Taysha Gene Therapies Inc (NAS:TSHA)
$ 5.02 -0.14 (-2.71%) Market Cap: 1.64 Bil Enterprise Value: 1.24 Bil PE Ratio: 0 PB Ratio: 4.22 GF Score: 33/100

Q4 2024 Taysha Gene Therapies Inc Earnings Call Transcript

Feb 26, 2025 / 01:30PM GMT
Release Date Price: $1.62 (-4.71%)
Operator

Ladies and gentlemen, good morning and welcome to the Taysha Gene Therapies full year 2024 conference call. (Operator Instructions).

As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Hayleigh Collins, Director, Head of corporate communications and Investor relations. Please go ahead.

Hayleigh Collins
Taysha Gene Therapies Inc - Director, Head of Corporate Communications and Investor Relations

Thank you. Good morning and welcome to Taysha's full year 2024 Financial Results and corporated conference call. Earlier today, Taysha issued a press release announcing financial results for the full year ended December 31, 2024.

A copy of this press release is available on the company's website and through our SEC filings. Joining me on today's call are Sean Nolan, Taysha's Chief Executive Officer; Sukumar Nagendran, President and Head of R&D; and Kamran Alam, Chief Financial Officer.

We will hold a question-and-answer session following our prepared remarks. Please note that on today's call we

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot